Pancreatic Cancer Research

Clinical trialObservationalUnknown

Multi-omics Characterization of Pancreatic Neuroendocrine Tumors and Carcinomas

Outcome
Outcome unknown
Phase
Observational
Status
Unknown
Study type
Observational
Start
1 December 2021
Listed end
30 June 2022
Enrollment
300 participants
Sites
1
Primary outcomes
Establishment of the number of tumor subgroups by integrating data from all multi-omics analyses
Sponsor type
Academic / other
Results posted
No
Last update
10 February 2022

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

In this work, the investigators count through the integrated multi-omics analysis to identify different tumor subgroups in pancreatic neuroendocrine tumors and carcinomas regardless of their grade and stage. To achieve this, they will resort to the use of next-generation sequencing approaches (RNAseq, then use of MCP Counter for the absolute quantification of the eight populations of immune cells in the tumor microenvironment), alterations in epigenetics with study of the methylome by MeDIP, ChIPseq, telomere (ALT) study, as well as correlation with peripheral blood neutrophil to lymphocyte ratio and immunohistochemistry data such as Ki67, p53, Rb, DAXX, ATRX, PDL1, immune cell labeling. This will be done on frozen or paraffin material. This work will provide a more complete biological picture of pancreatic neuroendocrine tumors and carcinomas.